Related Experiment Video
Updated: Jun 25, 2026
![Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F68356.jpg&w=3840&q=50)
Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
Published on: April 25, 2025
FBA-TPQ, a novel marine-derived compound as experimental therapy for prostate cancer
Feng Wang1, Scharri J Ezell, Yong Zhang
1Division of Clinical Pharmacology, Department of Pharmacology and Toxicology, University of Alabama at Birmingham, 1670 University Blvd, 113 Volker Hall, Birmingham, AL 35294, USA.
Abstract:
We recently synthesized a series of novel makaluvamine compounds, and found that the most potent was FBA-TPQ. The effects of FBA-TPQ on human (LNCaP and PC3) and murine (TRAMP C1) prostate cancer cells were evaluated. Potential mechanisms of action of the compound were also determined. FBA-TPQ exhibited dose-dependent cytotoxicity in the low micromolar range, inhibited proliferation, caused cell cycle arrest, and induced apoptosis in prostate cancer cell lines. The compound also decreased the expression of the androgen receptor and PSA. The results presented herein support the further development of FBA-TPQ as a novel agent for prostate cancer.
Insights
A novel makaluvamine compound, FBA-TPQ, shows significant potential against prostate cancer. It effectively reduced cancer cell growth, induced cell death, and lowered key cancer markers, supporting its further development.
Area of Science:
- Medicinal Chemistry
- Oncology
- Molecular Biology
Background:
- Prostate cancer remains a significant health concern with a need for novel therapeutic agents.
- Makaluvamine compounds represent a class of natural products with potential anticancer activities.
Purpose of the Study:
- To evaluate the efficacy and mechanisms of action of a novel synthesized makaluvamine compound, FBA-TPQ, against prostate cancer cells.
- To assess FBA-TPQ's cytotoxic, antiproliferative, and apoptotic effects on human and murine prostate cancer cell lines.
Main Methods:
- Synthesis and characterization of novel makaluvamine compounds.
- In vitro evaluation of FBA-TPQ cytotoxicity, proliferation inhibition, cell cycle analysis, and apoptosis induction in LNCaP, PC3, and TRAMP C1 cell lines.
- Assessment of androgen receptor (AR) and prostate-specific antigen (PSA) expression levels following FBA-TPQ treatment.
Main Results:
- FBA-TPQ demonstrated dose-dependent cytotoxicity against prostate cancer cells in the low micromolar range.
- The compound inhibited cell proliferation, induced cell cycle arrest, and promoted apoptosis in tested cell lines.
- FBA-TPQ treatment led to a decrease in the expression of androgen receptor and PSA.
Conclusions:
- FBA-TPQ exhibits potent anticancer effects against prostate cancer cells through multiple mechanisms.
- The compound's ability to target AR and PSA suggests a promising therapeutic strategy.
- FBA-TPQ warrants further investigation and development as a novel agent for prostate cancer treatment.
